@NilaJones @trendless @longcovid

Interesting study. Some notes:

-Only 31 patients in each arm
-No placebo control
-No objective measures of fatigue. (Self- reporting of fatigue can be unreliable - this will be influenced by a 'placebo effect' in the intervention group)
-Longer term follow-up might have been useful to see if the effect is maintained.
-The control arm had a higher BMI so might be expected to recover more slowly to begin with.
-A patient who couldn't tolerate amantadine was excluded. (It might have been better to keep them in the analysis - to show 'real life' results.

Note:
'COVID-related fatigue' in this study refers to fatigue 30-60 days post infection (so a bit different from long COVID).

Amantadine was previously tried in ME/CFS. Of 30 patients, half couldn't tolerate an 8 week course. In the remaining 15, there was no difference in symptoms.